(CDAX, Other, IXX GR)



Done		Value Indicators:	EUR	Warburg Risk Score:	2.5	Description:	
Buy		DCF:	52.95	Balance Sheet Score:	4.0	Init provides hardware and s	oftware
EUR <b>53.00</b>	(EUR 49.50)	FCF-Value Potential:	53.64	Market Liquidity Score:	1.0	solutions to public transport companies worldwide	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2024e
		Market cap:	366.4	Freefloat	51.81 %	Beta:	1.2
Price	EUR 36.80	No. of shares (m):	10.0	Mr. & Mrs. Dr. G.Greschner	42.58 %	Price / Book:	2.8 x
Upside	44.0 %	EV:	395.2	Remaining board members	4.71 %	Equity Ratio:	47 %
		Freefloat MC:	189.8	Employee shares	0.53 %	Net Fin. Debt / EBITDA:	0.5 x
		Ø Trad. Vol. (30d):	93.33 th	Own shares	0.37 %	Net Debt / EBITDA:	0.7 x

# Order intake gains momentum in Q3

Stated Figures Q3/2024:												
FY End: 31.12. in EUR m	Q3 24	Q3 24e	Q3 23	yoy	9M 24	9M 24e	9M 23	yoy				
Sales	63.6	60.4	53.4	19 %	178.1	174.9	143.0	25 %				
EBIT	5.0	4.8	5.5	-9 %	11.7	11.5	7.1	64 %				
Margin	7.9 %	8.0 %	10.3 %		6.6 %	6.6 %	5.0 %					
EPS	0.34	0.37	0.37	-8 %	0.81	0.85	0.50	62 %				

#### Comment on Figures:

- Q3 sales includes a first-time consolidation effect approx. EUR 1.7m from the DILAX acquisition in September
- Q3 EBIT declined as a result of product-mix effects and higher costs associated with the large delivery planned
- 9M EBIT was still up 64% yoy and the confirmed FY target range of EUR 24-28m should be well within reach

Init has published its Q3 figures, which were slightly above our expectations. Sales increased by 19.1% to EUR 63.6m (WRe EUR 60.4m), but was roughly in line with Q2 (EUR 64.0m). While Q2 benefitted from final deliveries for the large Houston project, Q3 included a minor first-time consolidation effect from DILAX (WRe EUR 1.7m). EBIT of EUR 5.0m was slightly above our estimate of EUR 4.8m, but below last year's figure of EUR 5.5m, due to product-mix effects and higher costs associated with the large delivery planned for the coming years.

The Q3 order intake was solid at EUR 57.3m after EUR 38.3m last year. While no major orders have been acquired yet, init has not lost any tender in its well-filled pipeline and we expect an additional major order in the coming quarter that should significantly increase the visibility for the coming years. The company has also gained new customers in Europe outside Germany. This confirms our expectation that, as well as the increased number of major projects in the tender pipeline, the market for smaller single-digit-million-volume projects has also recovered.

The FY guidance was confirmed (sales: EUR 240-260m, EBIT: EUR 24-28m). With 9M sales of EUR 178.1m and EBIT of only EUR 11.7m, this implies a notable increase in profitability in Q4 but this would not be uncommon considering the Q4 heavy seasonality of the high-margin aftersales business. Last year, init earned more than 65% of its annual EBIT in Q4. Even flat EBIT yoy would be sufficient to reach the lower end of the target range.


In addition, DILAX (annual sales approx. EUR 20m) was acquired in September (Q3 cash outflow for acquisitions EUR 7.1m) and should contribute fully to Q4 sales, although we are not yet expecting a notable EBIT contribution. We have now included DILAX in our forecast. As a result, we increase our DCF-based target to EUR 53 (from EUR 49.50) and confirm our Buy recommendation.

Changes in Es	Changes in Estimates:												
FY End: 31.12. in EUR m	2024e (old)	+/-	2025e (old)	+ / -	2026e (old)	+/-							
Sales	254.3	2.2 %	295.4	7.4 %	351.1	7.1 %							
EBIT	26.7	-0.8 %	37.5	4.1 %	47.7	5.5 %							
EPS	1.74	-1.1 %	2.48	4.4 %	3.19	5.6 %							

Q3

#### Comment on Changes:

- We have included the DILAX acquisition in our estimates with an estimated annual revenue of EUR 20m
- While the target should regain and increase profitability quickly, we expect
  a slightly dilutive effect on the group's margins



Rel. Performance vs CDAX:	
1 month:	6.2 %
6 months:	-4.8 %
Year to date:	11.9 %
Trailing 12 months:	17.0 %


FY End: 31.12.	CAGR							
in EUR m	(23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
Sales	21.3 %	180.7	176.7	191.3	210.8	259.8	317.4	376.1
Change Sales yoy		15.5 %	-2.2 %	8.3 %	10.2 %	23.2 %	22.2 %	18.5 %
Gross profit margin		34.4 %	35.5 %	40.0 %	38.1 %	36.7 %	37.1 %	36.4 %
EBITDA	28.0 %	28.9	27.4	31.2	32.3	39.2	54.0	67.6
Margin		16.0 %	15.5 %	16.3 %	15.3 %	15.1 %	17.0 %	18.0 %
EBIT	33.8 %	19.6	17.6	21.0	21.0	26.5	39.0	50.3
Margin		10.9 %	9.9 %	11.0 %	10.0 %	10.2 %	12.3 %	13.4 %
Net income	30.1 %	14.9	12.4	16.5	15.2	17.1	25.7	33.5
EPS	30.1 %	1.50	1.25	1.66	1.53	1.72	2.59	3.37
EPS adj.	30.1 %	1.50	1.25	1.66	1.53	1.72	2.59	3.37
DPS	12.6 %	0.55	0.55	0.70	0.70	0.75	0.85	1.00
Dividend Yield		2.0 %	1.4 %	2.7 %	2.4 %	2.0 %	2.3 %	2.7 %
FCFPS		1.74	1.24	1.45	-0.46	1.04	1.33	2.33
FCF / Market cap		6.3 %	3.1 %	5.7 %	-1.6 %	2.8 %	3.6 %	6.3 %
EV / Sales		1.7 x	2.3 x	1.4 x	1.5 x	1.5 x	1.2 x	1.0 x
EV / EBITDA		10.5 x	14.9 x	8.4 x	9.8 x	10.0 x	7.3 x	5.7 x
EV / EBIT		15.4 x	23.2 x	12.4 x	15.0 x	14.9 x	10.1 x	7.6 x
P/E		18.5 x	31.6 x	15.5 x	18.9 x	21.4 x	14.2 x	10.9 x
P / E adj.		18.5 x	31.6 x	15.5 x	18.9 x	21.4 x	14.2 x	10.9 x
FCF Potential Yield	1	7.3 %	5.0 %	9.3 %	7.9 %	7.0 %	9.6 %	12.3 %
Net Debt		25.0	13.2	5.3	25.6	27.1	26.2	16.4
ROCE (NOPAT)		14.5 %	11.4 %	14.4 %	12.3 %	12.3 %	16.7 %	20.0 %
Guidance:	Sales: EUR 2	40-260m, EB	IT: EUR 24-2	28m				

Analyst

13.11.24

Company events:






# **Company Background**

- Init is a leading supplier of hardware and software solutions for public transportation and covers a vast part of the value creation of its customers.
- Founded in 1983 as a university spin-off, init provides its services to more than 700 customers worldwide with >25 subsidiaries and offices and >900 employees
- 55% of group sales are generated with new projects. The remaining 45% consists of recurring after-sales and service revenues, such as delivery, maintenance, follow-up orders and operational services.
- The product portfolio includes electronic ticketing (45% of sales), intermodal transport control systems (25%), automated passenger counting (20%) and timetable planning and dispatching (5%).

# **Competitive Quality**

- Revenue growth is driven by structural mega-trends like smart city mobility concepts, urbanisation and growing environmental awareness.
- Focused business model with highly scalable modular platform solutions and low capex requirements
- Long-standing relationships with more than 700 customers worldwide yield significant cross-selling potential
- Large installed base includes >300 APC systems, >130 ICTS/RTPI, >120 personnel assignment, >100 planning, and >130 ticketing systems, while >120,000 equipped vehicles generate a profitable stream of recurring revenues
- Deep integration into its clients' processes along the value chain creates significant switching costs for init's customers





DCF model														
	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	
Sales	259.8	317.4	376.1	428.8	480.2	533.0	586.3	639.1	690.2	738.5	775.5	798.7	818.7	
Sales change	23.2 %	22.2 %	18.5 %	14.0 %	12.0 %	11.0 %	10.0 %	9.0 %	8.0 %	7.0 %	5.0 %	3.0 %	2.5 %	2.5 %
EBIT	26.5	39.0	50.3	55.7	60.0	64.0	67.4	70.3	72.5	73.9	77.5	79.9	81.9	
EBIT-margin	10.2 %	12.3 %	13.4 %	13.0 %	12.5 %	12.0 %	11.5 %	11.0 %	10.5 %	10.0 %	10.0 %	10.0 %	10.0 %	
Tax rate (EBT)	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	
NOPAT	18.5	27.3	35.2	39.0	42.0	44.8	47.2	49.2	50.7	51.7	54.3	55.9	57.3	
Depreciation	12.7	14.9	17.3	13.7	15.4	17.1	17.6	19.2	20.7	22.2	23.3	24.0	24.6	
in % of Sales	4.9 %	4.7 %	4.6 %	3.2 %	3.2 %	3.2 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
Changes in provisions	0.2	0.2	0.2	1.2	1.1	1.2	1.2	1.2	1.1	1.1	0.8	0.5	0.4	
Change in Liquidity from														
- Working Capital	6.8	14.5	16.4	13.2	13.0	12.9	12.5	11.8	14.3	13.5	10.3	6.5	5.6	
- Capex	14.0	14.2	12.5	14.6	15.4	16.0	17.6	19.2	20.7	22.2	23.3	24.0	24.6	
Capex in % of Sales	5.4 %	4.5 %	3.3 %	3.4 %	3.2 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
- Other	11.9	4.7	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-1.2	9.1	19.1	26.1	30.1	34.1	35.8	38.5	37.5	39.2	44.8	49.9	52.2	53
PV of FCF	-1.2	8.3	16.1	20.2	21.5	22.4	21.7	21.5	19.3	18.6	19.5	20.1	19.3	327
share of PVs		4.18 %						36.80	6 %					58.97 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2036e	228		
				Terminal Value	327		
Debt ratio	9.00 %	Financial Strength	1.20	Financial liabilities	45		
Cost of debt (after tax)	2.8 %	Liquidity (share)	1.30	Pension liabilities	8		
Market return	8.25 %	Cyclicality	0.90	Hybrid capital	0		
Risk free rate	2.75 %	Transparency	1.20	Minority interest	2		
		Others	1.20	Market val. of investments	0		
				Liquidity	27	No. of shares (m)	10.0
WACC	8.56 %	Beta	1.16	Equity Value	527	Value per share (EUR)	52.95

Sens	itivity Va	lue per Sh	are (EUR	)													
Terminal Growth Delta EBIT-margin																	
Beta	WACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.36	9.6 %	41.53	42.28	43.09	43.95	44.88	45.87	46.95	1.36	9.6 %	35.53	38.34	41.14	43.95	46.76	49.56	52.37
1.26	9.1 %	45.15	46.07	47.04	48.10	49.23	50.47	51.80	1.26	9.1 %	38.99	42.02	45.06	48.10	51.13	54.17	57.21
1.21	8.8 %	47.17	48.17	49.26	50.42	51.69	53.06	54.56	1.21	8.8 %	40.93	44.09	47.26	50.42	53.59	56.76	59.92
1.16	8.6 %	49.33	50.45	51.65	52.95	54.36	55.90	57.59	1.16	8.6 %	43.03	46.34	49.64	52.95	56.26	59.56	62.87
1.11	8.3 %	51.67	52.91	54.24	55.70	57.28	59.01	60.92	1.11	8.3 %	45.32	48.78	52.24	55.70	59.16	62.62	66.08
1.06	8.1 %	54.20	55.58	57.07	58.70	60.48	62.44	64.60	1.06	8.1 %	47.82	51.45	55.07	58.70	62.32	65.95	69.58
0.96	7.6 %	59.93	61.65	63.54	65.61	67.89	70.43	73.26	0.96	7.6 %	53.58	57.59	61.60	65.61	69.62	73.63	77.64

- The minority interest in CarMediaLab, TQA and SQM has not played a significant role in recent years
- To calculate the minorities, we multiplied the current book value with our target P/B 2022 of 4.0x
- Adjustments for the IFRS 16 effect are included in the "other" line
- Depreciation of usage rights is excluded from our D&A estimates in the transitional period



# Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net Income before minorities	14.9	12.4	16.5	15.2	17.1	25.7	33.5
+ Depreciation + Amortisation	9.2	9.8	10.2	11.2	12.7	14.9	17.3
- Net Interest Income	-0.9	-1.0	-0.7	-1.7	<b>-</b> 2.0	-2.3	-2.5
- Maintenance Capex	2.9	2.8	3.1	3.4	4.2	5.1	6.0
+ Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Free Cash Flow Potential	22.2	20.5	24.4	24.8	27.7	37.9	47.3
FCF Potential Yield (on market EV)	7.3 %	5.0 %	9.3 %	7.9 %	7.0 %	9.6 %	12.3 %
WACC	8.56 %	8.56 %	8.56 %	8.56 %	8.56 %	8.56 %	8.56 %
= Enterprise Value (EV)	302.5	408.3	261.5	314.8	394.2	393.3	383.5
= Fair Enterprise Value	259.4	239.4	284.7	289.2	324.0	442.2	552.1
- Net Debt (Cash)	18.0	18.0	18.0	18.0	19.3	18.2	8.2
- Pension Liabilities	7.6	7.6	7.6	7.6	7.8	8.0	8.2
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<ul> <li>Market value of minorities</li> </ul>	1.6	1.6	1.6	1.6	1.6	1.6	1.6
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	232.1	212.1	257.4	261.9	295.3	414.4	534.1
Number of shares, average	10.0	10.0	9.9	9.9	9.9	9.9	9.9
= Fair value per share (EUR)	23.31	21.30	25.93	26.39	29.75	41.75	53.82
premium (-) / discount (+) in %					-19.2 %	13.5 %	46.2 %
Sensitivity Fair value per Share (E	UR)						
1	1.56 % 16.55	15.06	18.43	18.76	21.21	30.09	39.25
1	0.56 % 18.38	16.75	20.43	20.80	23.49	33.20	43.14
!	9.56 % 20.59	18.79	22.86	23.26	26.25	36.97	47.84
WACC	8.56 % 23.31	21.30	25.93	26.39	29.75	41.75	53.82
	7.56 % 26.76	24.48	29.63	30.14	33.96	47.49	60.98
1	6.56 % 31.26	28.63	34.56	35.15	39.57	55.16	70.55
	5.56 % 37.37	34.27	41.27	41.97	47.21	65.58	83.56

- Maintenance capex is estimated at 1.6% of sales, reflecting low level of production equipment required
- The minority interest in iris, CarMediaLab, TQA and SQM has not played a significant role in recent years
- To calculate the minorities, we multiplied the current book value with our target P/B 2019 of 5.5x
- WACC is assumed at 7.4% consistent with cost of capital calculated in our DCF model
- Cash payments of EUR 7.1m for the DILAX acquisition are included in the "Others" Line

# init SE




Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	3.1 x	3.8 x	2.2 x	2.4 x	2.8 x	2.5 x	2.2 x
Book value per share ex intangibles	5.97	7.36	8.44	8.27	8.55	9.67	11.74
EV / Sales	1.7 x	2.3 x	1.4 x	1.5 x	1.5 x	1.2 x	1.0 x
EV / EBITDA	10.5 x	14.9 x	8.4 x	9.8 x	10.0 x	7.3 x	5.7 x
EV / EBIT	15.4 x	23.2 x	12.4 x	15.0 x	14.9 x	10.1 x	7.6 x
EV / EBIT adj.*	15.4 x	23.2 x	12.4 x	15.0 x	14.9 x	10.1 x	7.6 x
P/FCF	16.0 x	31.9 x	17.7 x	n.a.	35.3 x	27.6 x	15.8 x
P/E	18.5 x	31.6 x	15.5 x	18.9 x	21.4 x	14.2 x	10.9 x
P / E adj.*	18.5 x	31.6 x	15.5 x	18.9 x	21.4 x	14.2 x	10.9 x
Dividend Yield	2.0 %	1.4 %	2.7 %	2.4 %	2.0 %	2.3 %	2.7 %
FCF Potential Yield (on market EV)	7.3 %	5.0 %	9.3 %	7.9 %	7.0 %	9.6 %	12.3 %
*Adjustments made for: -							



Consolidated profit and loss							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Sales	180.7	176.7	191.3	210.8	259.8	317.4	376.1
Change Sales yoy	15.5 %	-2.2 %	8.3 %	10.2 %	23.2 %	22.2 %	18.5 %
COGS	118.5	114.0	114.7	130.4	164.5	199.6	239.2
Gross profit	62.2	62.7	76.6	80.4	95.3	117.8	136.9
Gross margin	34.4 %	35.5 %	40.0 %	38.1 %	36.7 %	37.1 %	36.4 %
Research and development	11.0	12.6	13.5	13.0	14.0	18.7	22.6
Sales and marketing	18.0	19.7	24.1	26.1	30.4	35.2	38.0
Administration expenses	16.8	17.4	20.4	23.4	27.8	28.9	30.5
Other operating expenses	0.3	0.4	1.6	0.4	1.0	1.0	1.2
Other operating income	3.5	4.9	4.1	3.6	4.4	5.1	5.6
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	28.9	27.4	31.2	32.3	39.2	54.0	67.6
Margin	16.0 %	15.5 %	16.3 %	15.3 %	15.1 %	17.0 %	18.0 %
Depreciation of fixed assets	7.1	7.7	7.8	8.3	8.8	9.8	11.7
EBITA	21.8	19.7	23.4	24.0	30.4	44.1	56.0
Amortisation of intangible assets	2.1	2.1	2.4	3.0	3.9	5.1	5.6
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	19.6	17.6	21.0	21.0	26.5	39.0	50.3
Margin	10.9 %	9.9 %	11.0 %	10.0 %	10.2 %	12.3 %	13.4 %
EBIT adj.	19.6	17.6	21.0	21.0	26.5	39.0	50.3
Interest income	0.1	0.0	0.0	0.3	0.4	0.2	0.2
Interest expenses	1.0	1.0	0.8	2.0	2.4	2.5	2.7
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	18.7	16.5	20.3	19.3	24.5	36.7	47.8
Margin	10.4 %	9.4 %	10.6 %	9.1 %	9.4 %	11.6 %	12.7 %
Total taxes	3.8	4.1	3.8	4.1	7.3	11.0	14.3
Net income from continuing operations	14.9	12.4	16.5	15.2	17.1	25.7	33.5
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	14.9	12.4	16.5	15.2	17.1	25.7	33.5
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	14.9	12.4	16.5	15.2	17.1	25.7	33.5
Margin	8.3 %	7.0 %	8.6 %	7.2 %	6.6 %	8.1 %	8.9 %
Number of shares, average	10.0	10.0	9.9	9.9	9.9	9.9	9.9
EPS	1.50	1.25	1.66	1.53	1.72	2.59	3.37
EPS adj.	1.50	1.25	1.66	1.53	1.72	2.59	3.37
*Adjustments made for:							

Guidance: Sales: EUR 240-260m, EBIT: EUR 24-28m


Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	23.5 %	25.5 %	29.0 %	28.2 %	26.5 %	24.8 %	23.0 %
Operating Leverage	1.4 x	4.8 x	2.4 x	0.0 x	1.1 x	2.1 x	1.6 x
EBITDA / Interest expenses	28.9 x	26.2 x	41.6 x	16.0 x	16.0 x	21.6 x	24.9 x
Tax rate (EBT)	20.2 %	24.8 %	18.6 %	21.4 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	36.6 %	44.0 %	42.1 %	45.9 %	43.5 %	32.8 %	29.7 %
Sales per Employee	179,056	167,449	181,282	199,811	228,015	257,933	282,996





Consolidated balance sheet							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026
Assets							
Goodwill and other intangible assets	31.1	29.3	32.5	38.0	43.9	47.6	48.5
thereof other intangible assets	18.6	16.8	17.3	15.8	21.7	25.4	26.3
thereof Goodwill	12.5	12.5	12.5	12.5	12.5	12.5	12.5
Property, plant and equipment	57.4	55.7	65.0	64.1	66.3	66.5	65.5
Financial assets	2.0	2.2	2.1	2.1	2.1	2.1	2.1
Other long-term assets	3.1	3.3	3.5	3.6	3.6	3.6	3.6
Fixed assets	93.5	90.4	103.2	107.8	115.9	119.8	119.7
Inventories	32.6	34.3	42.1	49.3	52.0	57.7	66.0
Accounts receivable	38.7	32.0	35.2	43.5	48.4	58.3	69.0
Liquid assets	32.3	28.2	40.1	27.3	26.0	27.2	37.2
Other short-term assets	29.6	31.9	25.1	32.6	32.6	32.6	32.6
Current assets	133.2	126.5	142.5	152.7	159.0	175.7	204.8
Total Assets	226.6	216.9	245.7	260.5	274.9	295.6	324.5
Liabilities and shareholders' equity							
Subscribed capital	10.0	10.0	10.0	10.0	10.0	10.0	10.0
Capital reserve	6.6	7.6	6.6	6.9	6.9	6.9	6.9
Retained earnings	80.3	87.3	98.4	106.2	116.3	134.6	159.6
Other equity components	-6.7	-2.6	1.4	-2.9	-4.4	-7.9	-11.5
Shareholders' equity	90.3	102.4	116.4	120.2	128.8	143.6	165.0
Minority interest	0.2	0.2	0.2	0.4	0.4	0.4	0.4
Total equity	90.5	102.6	116.6	120.6	129.2	144.0	165.4
Provisions	25.8	21.8	16.3	13.4	13.6	13.8	14.0
thereof provisions for pensions and similar obligations	11.8	10.8	7.3	7.6	7.8	8.0	8.2
Financial liabilities (total)	45.5	30.6	38.0	45.3	45.3	45.3	45.3
Short-term financial liabilities	17.5	14.1	18.5	19.7	19.7	19.7	19.7
Accounts payable	7.5	6.9	9.7	12.0	12.8	13.9	16.5
Other liabilities	57.2	55.0	65.1	69.3	73.9	78.6	83.3
Liabilities	136.1	114.3	129.2	139.9	145.6	151.6	159.1
Total liabilities and shareholders' equity	226.6	216.9	245.7	260.5	274.9	295.6	324.5


Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	1.5 x	1.6 x	1.5 x	1.5 x	1.7 x	1.9 x	2.1 x
Capital Employed Turnover	1.6 x	1.5 x	1.6 x	1.4 x	1.7 x	1.9 x	2.1 x
ROA	16.0 %	13.7 %	16.0 %	14.1 %	14.8 %	21.5 %	27.9 %
Return on Capital							
ROCE (NOPAT)	14.5 %	11.4 %	14.4 %	12.3 %	12.3 %	16.7 %	20.0 %
ROE	17.0 %	12.9 %	15.1 %	12.8 %	13.7 %	18.9 %	21.7 %
Adj. ROE	17.0 %	12.9 %	15.1 %	12.8 %	13.7 %	18.9 %	21.7 %
Balance sheet quality							
Net Debt	25.0	13.2	5.3	25.6	27.1	26.2	16.4
Net Financial Debt	13.3	2.4	-2.0	18.0	19.3	18.2	8.2
Net Gearing	27.7 %	12.8 %	4.5 %	21.3 %	21.0 %	18.2 %	9.9 %
Net Fin. Debt / EBITDA	45.9 %	8.6 %	n.a.	55.8 %	49.2 %	33.7 %	12.1 %
Book Value / Share	9.1	10.3	11.7	12.1	13.0	14.5	16.6
Book value per share ex intangibles	6.0	7.4	8.4	8.3	8.6	9.7	11.7





Consolidated cash flow statement							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net income	14.9	12.4	16.5	15.2	17.1	25.7	33.5
Depreciation of fixed assets	9.2	9.2	8.9	8.3	8.8	9.8	11.7
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	2.1	2.1	2.4	3.0	3.9	5.1	5.6
Increase/decrease in long-term provisions	2.7	-4.3	<b>-</b> 5.7	<b>-</b> 2.9	0.2	0.2	0.2
Other non-cash income and expenses	-0.7	-0.7	1.4	1.6	-0.2	-0.2	-0.2
Cash Flow before NWC change	28.3	18.8	23.5	25.0	29.8	40.6	50.8
Increase / decrease in inventory	-4.1	-0.7	-7.1	-7.8	<b>-</b> 2.7	<b>-</b> 5.7	-8.3
Increase / decrease in accounts receivable	1.7	11.3	5.9	-16.6	-4.9	<b>-</b> 9.9	-10.7
Increase / decrease in accounts payable	-0.5	<b>-</b> 9.7	2.6	3.0	0.8	1.1	2.6
Increase / decrease in other working capital positions	-1.0	-3.7	-0.6	4.3	1.3	1.3	1.3
Increase / decrease in working capital (total)	-3.9	-2.8	0.9	-17.1	<b>-</b> 5.5	-13.2	-15.1
Net cash provided by operating activities [1]	24.4	16.0	24.4	8.0	24.4	27.4	35.7
Investments in intangible assets	-1.6	-1.6	-5.6	-8.4	-9.8	-8.8	-6.5
Investments in property, plant and equipment	-5.5	-2.1	-16.6	-7.8	-8.9	-10.1	-10.7
Payments for acquisitions	-7.8	0.0	-1.1	-1.1	0.0	0.0	0.0
Financial investments	0.0	0.0	-0.2	-0.1	0.0	0.0	0.0
Income from asset disposals	0.3	0.3	0.3	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-14.6	-3.4	-10.5	-13.5	-14.0	-14.2	-12.5
Change in financial liabilities	7.4	-8.1	8.6	7.3	0.0	0.0	0.0
Dividends paid	-4.0	-5.5	-5.5	-6.9	-7.0	-7.4	-8.4
Purchase of own shares	-2.2	-0.7	-1.8	<b>-</b> 2.7	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.2	0.0	0.0	0.0
Other	-3.9	-3.5	-3.5	-4.7	-4.7	-4.7	-4.7
Net cash provided by financing activities [3]	-2.8	-17.7	-2.2	-6.8	-11.6	-12.1	-13.1
Change in liquid funds [1]+[2]+[3]	7.0	-5.1	11.6	-12.3	-1.3	1.1	10.0
Effects of exchange-rate changes on cash	-1.0	1.1	0.3	-0.5	0.0	0.0	0.0
Cash and cash equivalent at end of period	32.2	28.2	40.1	27.3	26.0	27.1	37.2

Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	17.3	12.3	14.4	-4.5	10.3	13.2	23.1
Free Cash Flow / Sales	9.6 %	7.0 %	7.5 %	<b>-</b> 2.1 %	4.0 %	4.2 %	6.2 %
Free Cash Flow Potential	22.2	20.5	24.4	24.8	27.7	37.9	47.3
Free Cash Flow / Net Profit	115.8 %	99.3 %	87.5 %	-29.8 %	60.4 %	51.5 %	69.2 %
Interest Received / Avg. Cash	0.3 %	0.1 %	0.1 %	0.8 %	1.5 %	0.8 %	0.6 %
Interest Paid / Avg. Debt	2.6 %	2.7 %	2.2 %	4.8 %	5.4 %	5.5 %	6.0 %
Management of Funds							
Investment ratio	4.0 %	2.1 %	11.6 %	7.7 %	7.2 %	5.9 %	4.6 %
Maint. Capex / Sales	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %	1.6 %
Capex / Dep	77.3 %	37.4 %	217.8 %	144.8 %	146.9 %	126.5 %	99.4 %
Avg. Working Capital / Sales	34.3 %	33.8 %	32.3 %	34.2 %	31.2 %	28.9 %	28.5 %
Trade Debtors / Trade Creditors	512.5 %	462.2 %	361.4 %	363.6 %	378.1 %	419.4 %	418.2 %
Inventory Turnover	3.6 x	3.3 x	2.7 x	2.6 x	3.2 x	3.5 x	3.6 x
Receivables collection period (days)	78	66	67	75	68	67	67
Payables payment period (days)	23	22	31	33	28	25	25
Cash conversion cycle (Days)	151	146	166	171	148	141	138





# **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

# **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

# SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
init SE	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005759807.htm



# INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.

WARRIEG RESEARCH GMRH -	- ANALYSED RESEARCH UNIVERSE BY RATING
WANDONG NEGERINGII GIVIDII -	

Rating	Number of stocks	% of Universe
Buy	140	70
Hold	44	22
Sell	10	5
Rating suspended	7	3
Total	201	100

# WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	40	73
Hold	10	18
Sell	2	4
Rating suspended	3	5
Total	55	100

# PRICE AND RATING HISTORY INIT SE AS OF 13.11.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	<b>Hannes Müller</b> Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks. Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Stefan Augustin	+49 40 309537-168	Malte Schaumann	+49 40 309537-170
Cap. Goods, Engineering	saugustin@warburg-research.com	Technology	mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs	+49 40 309537-175	Simon Stippig	+49 40 309537-265
Industrials & Transportation  Dr. Christian Ehmann	ccohrs@warburg-research.com +49 40 309537-167	Real Estate, Telco  Marc-René Tonn	sstippig@warburg-research.com +49 40 309537-259
BioTech, Life Science	cehmann@warburg-research.com	Automobiles, Car Suppliers	mtonn@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Robert-Jan van der Horst Technology	+49 40 309537-290 rvanderhorst@warburg-research.com
Jörg Philipp Frey	+49 40 309537-258	Andreas Wolf	+49 40 309537-140
Retail, Consumer Goods	jfrey@warburg-research.com	Software, IT	awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com		
Fabio Hölscher	+49 40 309537-240		
Automobiles, Car Suppliers  Philipp Kaiser	fhoelscher@warburg-research.com +49 40 309537-260		
Real Estate, Construction	pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
INSTITUTIONAL EQUIT	TY SALES		
Klaus Schilling	+49 69 5050-7400	Sascha Propp	+49 40 3282-2656
Head of Equity Sales, Germany Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	France	spropp@mmwarburg.com
United Kingdom	tbeckmann@mmwarburg.com		
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com		
Matthias Fritsch	+49 40 3282-2696	Leyan Ilkbahar	+49 40 3282-2695
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis Germany	+49 40 3282-2649 rmichaelis@mmwarburg.com	Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Roman Alexander Niklas	+49 69 5050-7412	Juliane Niemann	+49 40 3282-2694
Switzerland, Poland, Italy	rniklas@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOR	
Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com	Marcel Magiera Designated Sponsoring	+49 40 3282-2662 mmagiera@mmwarburg.com
Rico Müller	+49 40 3282-2685	Sebastian Schulz	+49 40 3282-2631
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast Sales Trading	+49 40 3282-2701 bquast@mmwarburg.com	Jörg Treptow Designated Sponsoring	+49 40 3282-2658 jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fo			, , , , , , , , , , , , , , , , , , , ,
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please contact	ot:		
Andrea Schaper Sales Assistance	+49 40 3282-2632	Kerstin Muthig Sales Assistance	+49 40 3282-2703
Calco Assistante	aschaper@mmwarburg.com	Odico Mooioldiile	kmuthig@mmwarburg.com